Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

56.34USD
11 Dec 2017
Change (% chg)

$0.77 (+1.39%)
Prev Close
$55.57
Open
$55.57
Day's High
$56.63
Day's Low
$55.57
Volume
3,983,487
Avg. Vol
3,163,623
52-wk High
$66.80
52-wk Low
$53.63

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

Merck raises stakes in lung cancer as rivals close in

LOS ANGELES Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.

12:27pm GMT

Merck raises stakes in lung cancer as rivals close in

LOS ANGELES Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer.

6:24am GMT

BRIEF-Neon Therapeutics To Collaborate with Merk on Clinical Trial

* NEON THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK

07 Dec 2017

Nestle to buy vitamin maker Atrium Innovations for $2.3 billion

LONDON Nestle is buying Canadian vitamin maker Atrium Innovations for $2.3 billion (£1.7 billion), expanding its presence in consumer healthcare as it seeks to offset weakness in packaged foods.

05 Dec 2017

BRIEF-Merck's Mavenclad (Cladribine Tablets) Approved For Relapsing-Remitting Multiple Sclerosis In Canada

* MERCK'S MAVENCLAD (CLADRIBINE TABLETS) APPROVED FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA Source text for Eikon: Further company coverage:

04 Dec 2017

UPDATE 2-Health secretary nominee Azar says lowering drug prices a top priority

WASHINGTON, Nov 29 Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, promised on Wednesday to lower drug prices and said he was unaware of any efforts to sabotage the healthcare law passed under former President Barack Obama.

29 Nov 2017

BRIEF-Merck Announces $10 Billion Share Repurchase Authorization

* MERCK ANNOUNCES INCREASED QUARTERLY DIVIDEND AND $10 BILLION SHARE REPURCHASE AUTHORIZATION

28 Nov 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

27 Nov 2017

As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

LONDON Britain pitched a new strategy for industry on Monday, pledging greater state intervention to tackle weak productivity and to help the world's sixth largest economy cope with the upheaval of leaving the European Union.

27 Nov 2017

UPDATE 2-As Brexit looms, UK pitches new industry plan, wins support from Merck, Qiagen

* Drug industry remains concerned about Brexit impact (Adds Prime Minister, Business Secretary comments, reaction)

27 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $141.01 +0.42
Pfizer Inc. (PFE.N) $36.21 +0.47
AbbVie Inc (ABBV.N) $96.47 +0.52
Eli Lilly and Co (LLY.N) $86.59 +0.14
Bristol-Myers Squibb Co (BMY.N) $63.02 +0.60
Bristol-Myers Squibb Co (BMYMP.PK) $1,060.00 +4.55

Earnings vs. Estimates